Zepbound or CPAP? Which Is the Best Sleep Apnea Treatment?

April 28, 2026 By Wellue Health

Sleep apnea treatment used to be straightforward: if you were diagnosed, you were typically prescribed a CPAP machine.

That model is now changing. In late 2024, the FDA announced that "the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in combination with a reduced-calorie diet and increased physical activity." [1]

This raises an important question: If a medication can treat sleep apnea, does CPAP still matter? To answer that, we need to look at how these treatments actually work — and who they work for.

1. what exactly is zepbound?

Zepbound (tirzepatide) is a once-weekly injectable medication originally developed for weight loss and metabolic disease. In simple terms, it works by mimicking natural hormones (GLP-1 and GIP) that reduce appetite, help regulate blood sugar, and lead to significant weight loss. These hormones play a role in how your body signals fullness and processes nutrients, meaning you tend to feel satisfied sooner and consume fewer calories without constantly thinking about food. At the same time, the medication helps improve how the body handles glucose, which is especially important for people with metabolic issues. Over time, these combined effects can lead to meaningful and sustained weight reduction.

Clinical trials behind the approval showed that over 52 weeks:

• Patients had statistically significant reductions in apnea events (AHI)

• Many experienced improvement in symptoms

• A portion reached remission or mild disease status

However, two key limitations are often overlooked:

• It is only approved for patients with obesity

• It must be used alongside diet and lifestyle changes

This is important because obesity is closely linked to OSA.

2. why obesity matters

Obesity is widely recognized as a major risk factor for OSA. Some widely cited cardiovascular research suggests that: “≈70% of OSA patients are obese” [2]

Obstructive sleep apnea occurs when the airway collapses during sleep. One of the most important contributing factors is excess tissue around the neck and airway, which is strongly associated with body weight. According to the FDA: “Zepbound works… to reduce appetite and food intake. By reducing body weight, studies show that Zepbound also improves OSA” [1.B]

However, the reality is more nuanced. If around 70% of patients are obese, that means a significant portion of OSA patients are not. In these individuals, sleep apnea is driven by other factors, including:

• Airway anatomy (narrow airway, large tongue, soft tissue collapse)

• Craniofacial structure (jaw position, nasal structure)

• Neuromuscular control during sleep

Even in obese patients, successful weight reduction does not guarantee complete resolution of OSA. One reason is that persistent anatomical abnormalities — such as a narrowed upper airway or craniofacial variations — can continue to trigger airway collapse regardless of BMI changes. This is why modern clinical understanding treats OSA as a multifactorial disease, not just a weight-related condition.

3. cpap is still widely used in clinical practice

More than a year after Zepbound’s FDA approval for OSA, CPAP machine remains the gold standard therapy in clinical practice — “CPAP is the most common and reliable method of treating sleep apnea”[3]

To understand why, we need to look at the mechanism of the disease itself. Obstructive sleep apnea is fundamentally a mechanical problem:

• The airway collapses during sleep

• Airflow stops Oxygen levels drop

• The brain triggers arousal

CPAP directly addresses this by delivering continuous air pressure that keeps the airway open during each breath. There are several reasons for its continued dominance:

• It works immediately (often from the first night)

• It works regardless of cause (weight, anatomy, or neuromuscular factors)

• It provides predictable control of airway patency

Unlike medication-based approaches, CPAP does not rely on systemic changes — it directly prevents breathing interruptions.

4. zepbound vs cpap: not a direct competition

It is tempting to frame Zepbound and CPAP as competing options. But clinically, they address different layers of the same problem.

Zepbound:

• Modifies long-term risk (body weight)

• Works indirectly

• Takes time

CPAP:

• Controls airway collapse

• Works immediately

• Directly prevents apnea events

This leads to a key distinction: CPAP treats the manifestation of the disease, while Zepbound modifies one of its underlying drivers. In a condition where repeated oxygen desaturation can impact cardiovascular health, timing matters.

5. a more realistic model: combination therapy

One often overlooked detail in Zepbound clinical trials is that patients were studied both with and without positive airway pressure (PAP) therapy. This reflects how treatment is evolving in real-world clinical practice. Rather than replacing CPAP, newer therapies are increasingly used alongside it.

The logic is straightforward:

• CPAP stabilizes breathing immediately

• Zepbound reduces contributing factors over time

This creates a layered strategy: short-term control + long-term improvement. In patients with obesity, this combination may:

• Reduce apnea severity

• Improve CPAP tolerance

• Potentially lower required pressure settings

Therefore, combination therapy becomes particularly valuable:

• CPAP ensures immediate, reliable airway support

• Zepbound reduces underlying contributing factors

Together, they can complement each other — improving both effectiveness and long-term adherence.

final takeaway

Zepbound represents a meaningful advance in sleep apnea treatment. It introduces, for the first time, a licensed medication that improves OSA outcomes by targeting weight—one of the condition’s most important modifiable risk factors. But it does not replace mechanical airway support with CPAP; instead, it expands the overall OSA treatment landscape.

A more accurate way to understand the current state of OSA care is this: CPAP controls the airway, while Zepbound modifies underlying risk factors. Used together, they may offer a more complete, personalized approach to treatment. For most patients with obesity-related moderate to severe OSA, the most effective strategy is not choosing between the two—it is understanding how they work together to improve outcomes.

footnotes

1. U.S. Food and Drug Administration. FDA approves first medication for obstructive sleep apnea.

https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea

2. Wolk R, Shamsuzzaman ASM, Somers VK. Obesity, obstructive sleep apnea, and hypertension. Hypertension.

https://www.ahajournals.org/doi/10.1161/01.hyp.0000101686.98973.a3

3. Mayo Clinic. Sleep apnea - Diagnosis & treatment.

https://www.mayoclinic.org/diseases-conditions/sleep-apnea/diagnosis-treatment/drc-20377636

explore solutions for better sleep health

Sleep apnea and poor sleep quality often require a combination of approaches. Whether you’re looking for airway support, improved comfort, or long-term sleep optimization, our products are designed to support different needs across your sleep journey.